Biosimilar Puns

Amneal Pharmaceuticals (AMRX under $5.50) under the radar is a small cap developer of high end biosimilars (and a possible buyout candidate) of blockbuster drugs such as Avastin

https://finance.yahoo.com/news/amneals-avastin-referred-biosimilar-under-143159652.html

Also developing prefilled syringe autoinjecters to facilitate patients taking drugs

https://finance.yahoo.com/news/amneal-announces-dihydroergotamine-dhe-autoinjector-120000789.html

IMHO; the short term ( 1 year) potential for this stock could be 50pct and long term it could even be a buyout candidate.

Hi. My daughter is 15 and has Crohn’s Disease. She’s had it since she was 5 and we are on our 10th year of every 6 week Remicade infusions. She also takes 50mg of 6MP each night because she runs out of Remicade about week 4.

I work for my insurance company but we use Cigna for our PPO and I received a letter from them over the weekend that they no longer consider Remicade as medically necessary and want us to switch to a biosimilar.

I’m trying not to freak out but I have been working so hard on keeping her well all these years and now insurance just wants to save a buck.

Her dad died when he was 38 because he didn’t keep up with medication for his Crohn’s. She’s done so well on Remicade for so long that I’m scared to switch. What if it doesn’t work as well? What if she has a reaction? What if it speeds up the inevitable of Remicade type medications no longer working for her?

Anybody who has been in a similar situation have any stories or advice?

Update: All of your comments were really helpful!

I have now called pharmacy back and rebooked Hyrimoz training/first dose for 9 days after Moderna. I had a pretty bad AS flare after my first vaccine and I want to give the biosimilar a chance to work well when I’m not already recovering from something so specific as a post-vaccine flare. Very grateful to be in a position to be vaccinated and trying a new AS med, just needed a little fine-tuning on timing :)

Thanks again!

Has anyone been transferred to Amgevita, Hulio or Idacio biosimilars so far? If yes, please let us know if any:

• adverse reactions,
• change in efficacy in comparison to Humira,
• if you know please post link to any clinical trial of a.m. meds. Thanks

A hidden GEM among the biotech breakdown

I've been watching this one for a couple weeks and I see the possible capitulation on downside today so I started a position. Some very high quality biotech's have been pulled down with the sector and this one has the best set-up imo. Coherus BioSciences, Inc. (NASDAQ: CHRS)

Market Cap: 1.03B

Sales: $475M

Net Income: $132.2M

P/E: 8.75

Shares O/S: 73M

Shares in float: 64.13M Shares short (Float) 21.17% Note* this number has been going down slightly signaling process of covering. Now that usually is mandated by the 15th or1st of the month. With the 15Th approaching this could get interesting. Note also the RSI (14) is at 33.64 which is extremely oversold.

The last 3 years CHRS has had high revenue and EPS growth.

I am currently putting together some DD now on their pipeline and commercial products. Up vote if you want to see this report.

Not investment advice. I love the stock. I own commons and calls.

DD on CHRS part 2 biosimilars are the generic version you get at the pharmacy and these guys are taking market share, see link below. more coming. https://www.reddit.com/user/SituationLive4406/comments/mo5n51/dd_biosimilars_are_the_generic_version_most_of_us/

I own commons and calls, This not a paid post and not advice.

I just found this sub and am so glad I did. Immersing myself in a supportive, "we're right there with you" community is really what I need right now.

So after a month and a half of excruciating pain I have just been diagnosed with moderate Crohn's colitis. I'm in the process of getting everything in order to start Inflectra.

I have so many fears and so many questions. I'm scared about the infusions. I'm scared about future flares- how often, how long will they last? I'm scared about complications. I'm scared of managing this disease at work (I'm a teacher so I pretty much have zero control of my schedule or daily routine). I'm scared that I won't be able to manage stress which will contribute to flares.

The pain has subsided considerably, but I haven't started treatment yet. I know symptoms are not necessarily indicative of what's going on inside your body, but is it normal to go from extreme pain to almost nothing, over the course of about a month, without treatment? I did mention it to my GI and he rather adamantly insisted that my colon is riddled with inflammation, ulcers, cobblestone, and abscesses despite feeling better and reiterated that symptoms do not necessarily represent what's going on.

Any thoughts/advice are more than welcome.

I'm 17, turning 18 in august. my doctor said i need to switch to a biosimilar humira when i turn 18 in order to have coverage. (she said it just happened recently that we have to switch to the biosimilar in alberta Canada). i forgot to ask her what the biosimilar is called that i will be moving to. i did some research and there are Amgentiva, Hadlima, Hulio, Hyrimoz, Idacio. Does anyone have any experience with these? I'm sure my old or new doc will probably choose one for me, but is there really a difference between them? anything helps!

Introduced: Sponsor: Rep. Tony Cárdenas [D-CA29]

This bill was referred to the House Committee on Energy and Commerce and House Committee on Ways and Means which will consider it before sending it to the House floor for consideration.

Rep. Tony Cárdenas [D-CA29] is a member of the House Committee on Energy and Commerce.

Govtrack.us Summary

I am on a very high dose of inflectra 1 vial per 10kg with 4 weeks frequency. I was tested positive for Covid last month. This was my experience. My fever would go down for few hours after I take two tablets of extra-strength Tylenol. Morning used to be good and fever would kick in around 2 pm. Fever ranges from 99.5 to 100.5 C.

Day 1: Started feeling fever in the evening.

Day 2: Fever. Booked Covid test.

Day 3: Fever. Gave the Covid test.

Day 4: Fever and Cough.

Day 5: Got positive result. Fever, cough, sore throat.

Day 6: Voice is gone because of coughing.

Day 7: Started having trouble with breathing after doing heaving task and eating.

Day 8 - 11: Symptoms continued. Sometimes I would see blood in phlegm that came with cough. Also had pain in the center of chest likely because of coughing.

Day 12: First day without fever. But cough and sore throat stayed.

Day 13 - 16: Colitis symptoms kicked in. Blood in stool and constipation.

Day 17: Called GI. He said I am free of covid and cough will likely stay for few weeks as my body recover.

Day 18: Went and had inflectra infusion.

After a week: I still have a cough.

Hope this helps.

Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, their goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus’ commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Damn that needle was a long motherfucker! Not looking forward to that again in two weeks time!

Hope this works, would be nice to play guitar again soon :)

My boyfriend was on Remicade for 4 years and it worked very well, but our insurance will stop covering Remicade so he has to switch to biosimilar. I am very worried and not sure how this will affect his health. Is there anyone out there who had to switch from Remicade to biosimilar?

The Top 5 Biosimilar Articles for the Week of February 1

February 5, 2021

Here are the top 5 biosimilar articles for the week of February 1, 2021.

Play Video

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars. Here are the top 5 biosimilar articles for the week of February 1, 2021. Number 5: In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace. Number 4: Using a combination of step therapy and parity reimbursement, pharmacy benefit manager (PBM) Magellan Rx Management has achieved a 90% success rate in biosimilar authorizations for the period from July 2019 to May 2020. Number 3: Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January. Number 2: Pfizer's investment in biosimilars is starting to pay off, as it now ranks these agents among its top revenue drivers for the fourth quarter of 2020. Number 1: HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion Healthcare, discussed how the company’s adalimumab biosimilar candidate, CT-P17, stands out from the competition. To read all of these articles and more, visit centerforbiosimilars.com.

Important excerpt's from Earnings call Q3

Coherus celebrated its 10th year anniversary, and I'm thrilled by what we have accomplished at this milestone. Coherus is a fully integrated company with competencies in research, development and commercialization. And we are successfully fulfilling our mission to deliver value to patients by providing them with access to cost-effective drugs that can have a major impact on their lives. Moreover, our UDENYCA business is generating significant cash flow, which will fund pipeline investments to expand our addressable market opportunity from $4 billion to about $30 billion over our 5-year planning period.

We ended the quarter with cash, cash equivalents and short-term investments of $503 million, above the $0.5 billion mark for the first time in the company's history. UDENYCA's net product revenue was $114 million in the third quarter. Our commercial team continues to execute and to demonstrate a remarkable ability to adapt to the volatility of the COVID-19 environment. Compared to the prior quarter, the overall pegfilgrastim market declined by 7%. UDENYCA x factory unit sales rose by 2%, and our market share increased from 20% to 22%. As we approach two years of experience commercializing UDENYCA, I'd like to reflect on the question that many of you were asking us at launch. Can a small first launch, pure-play biosimilar company, compete with much larger entrenched originators and established biosimilar competitors. With UDENYCA achieving 20% exit market share, after the first year and approaching a market share range of 23% to 24% as we close out year two, I believe we have answered that question affirmatively.

Dennis M. Lanfear -- President, Chief Executive Officer and Chairman (potential 2021 milestones/catalysts = 3+)

"I'd like to provide a few updates and highlights regarding our pipeline of biosimilar product candidates. We've made very good progress across our pipeline, particularly on programs where Coherus' sponsor with the FDA. Our Avastin biosimilar, which we in license from Innovent, will further expand our oncology franchise and leverage our commercial infrastructure. As the U.S. sponsor of the product, we are continuing to work with the Innovent toward Coherus' expected BLA filing next year with the FDA. Precise timing of our filing is dependent on the scheduling and outcome of required interactions with the FDA, the completion of three-way pharmacokinetic study as well as the completion

AMRX, Amneal Pharmaceuticals is an under the radar is a small cap developer of high end biosimilars (and a possible buyout candidate) of blockbuster drugs such as Avastin

https://finance.yahoo.com/news/amneals-avastin-referred-biosimilar-under-143159652.html

Also developing prefilled syringe autoinjecters to facilitate patients taking drugs

https://finance.yahoo.com/news/amneal-announces-dihydroergotamine-dhe-autoinjector-120000789.html

IMHO; the short term ( 1 year) potential for this stock could be 50pct and long term it could even be a buyout candidate.